Schroder Investment Management Group’s Maze Therapeutics MAZE Stock Holding History

Schroder Investment Management Group’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.08M	Buy	+37,181	New	+$1.64M	﹤0.01%	1022

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Schroder Investment Management Group's MAZE Position: Q1 2026 in Review

Schroder Investment Management Group opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 37,181 shares worth $1.08M. The stake represents ﹤0.01% of the portfolio and ranks #1022 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Schroder Investment Management Group held 37,181 shares of Maze Therapeutics worth $1.08M as of Q1 2026.
Maze Therapeutics was a new Schroder Investment Management Group position in Q1 2026.
Maze Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #1022 holding.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.